Clinical studies on COVID‐19 patients with hematological cancers, who have impaired humoral immunity due to B‐cell‐depleting medication, have shown that the presence of CD8+ T cell responses is associated with higher survival rates [143]. Here, CD8A is linked to COVID-19.